XML 47 R22.htm IDEA: XBRL DOCUMENT
v3.25.1

Income Taxes | 12 Months Ended
--- | ---
Jan. 31, 2025
Income Tax Disclosure [Abstract] |
Income Taxes | Income Taxes The components of loss before income taxes were as follows (in thousands):
| Fiscal Year Ended January 31,
| 2025 |  | 2024 |  | 2023
U.S. | $ | (1,341,798) |  |  | $ | (875,703) |  |  | $ | (851,538) |
Foreign | 56,699 |  |  | 26,480 |  |  | 35,545 |
Loss before income taxes | $ | (1,285,099) |  |  | $ | (849,223) |  |  | $ | (815,993) |
The provision for (benefit from) income taxes consists of the following (in thousands):
| Fiscal Year Ended January 31,
| 2025 |  | 2024 |  | 2023
Current provision: |  |  |  |  |
State | $ | 806 |  |  | $ | 754 |  |  | $ | 626 |
Foreign | 10,978 |  |  | 14,775 |  |  | 7,571 |
Deferred benefit: |  |  |  |  |
Federal | (6,294) |  |  | (15,376) |  |  | (21,647) |
State | (1,011) |  |  | (4,700) |  |  | (4,410) |
Foreign | (366) |  |  | (6,686) |  |  | (607) |
Provision for (benefit from) income taxes | $ | 4,113 |  |  | $ | (11,233) |  |  | $ | (18,467) |
The effective income tax rate differs from the federal statutory income tax rate applied to the loss before income taxes due to the following (in thousands):
| Fiscal Year Ended January 31,
| 2025 |  | 2024 |  | 2023
Income tax benefit computed at federal statutory rate | $ | (269,871) |  |  | $ | (178,337) |  |  | $ | (171,359) |
State taxes, net of federal benefit | 33,910 |  |  | 26,380 |  |  | 14,948 |
Research and development credits | (133,266) |  |  | (101,725) |  |  | (58,136) |
Stock-based compensation | (7,667) |  |  | (148,600) |  |  | (71,295) |
Change in valuation allowance | 363,422 |  |  | 371,767 |  |  | 213,532 |
IRC Section 59A waived deductions | — |  |  | 11,550 |  |  | 49,476 |
Other | 17,585 |  |  | 7,732 |  |  | 4,367 |
Provision for (benefit from) income taxes | $ | 4,113 |  |  | $ | (11,233) |  |  | $ | (18,467) |
A valuation allowance has been recognized to offset the Company’s deferred tax assets, as necessary, by the amount of any tax benefits that, based on evidence, are not expected to be realized. As of January 31, 2025 and 2024, the Company believes it is more likely than not that its U.S. and U.K. deferred tax assets will not be fully realizable and continues to maintain a full valuation allowance against these net deferred tax assets. Significant components of the Company’s deferred tax assets and deferred tax liabilities are shown below (in thousands):
| January 31, 2025 |  | January 31, 2024
Deferred tax assets: |  |  |
Net operating losses carryforwards | $ | 1,707,649 |  |  | $ | 1,673,213 |
Capitalized research and development | 725,823 |  |  | 420,491 |
Tax credit carryforwards | 511,504 |  |  | 376,804 |
Operating lease liabilities | 104,517 |  |  | 54,008 |
Deferred revenue | 95,779 |  |  | 82,683 |
Capped call transactions | 45,032 |  |  | — |
Stock-based compensation | 36,044 |  |  | 109,446 |
Net unrealized losses on strategic investments | 6,143 |  |  | 2,443 |
Other | 50,790 |  |  | 31,776 |
Total deferred tax assets | 3,283,281 |  |  | 2,750,864 |
Less: valuation allowance | (3,104,505) |  |  | (2,621,009) |
Net deferred tax assets | 178,776 |  |  | 129,855 |
Deferred tax liabilities: |  |  |
Intangible assets | (27,481) |  |  | (39,173) |
Deferred commissions | (56,662) |  |  | (41,609) |
Operating lease right-of-use assets | (94,997) |  |  | (48,629) |
Other | (234) |  |  | (1,326) |
Total deferred tax liabilities | (179,374) |  |  | (130,737) |
Net deferred tax liabilities | $ | (598) |  |  | $ | (882) |
The valuation allowance was $3.1 billion and $2.6 billion as of January 31, 2025 and 2024, respectively, primarily relating to U.S. federal and state net operating loss carryforwards, capitalized research and development, and tax credit carryforwards. The valuation allowance increased $483.5 million during the fiscal year ended January 31, 2025, primarily due to increased capitalized research and development and tax credit carryforwards. The valuation allowance increased $520.4 million and $241.9 million during the fiscal years ended January 31, 2024 and 2023, respectively, primarily due to increased capitalized research and development, U.S. federal and state net operating loss carryforwards, and tax credit carryforwards. As of January 31, 2025, the Company had U.S. federal, state, and foreign net operating loss carryforwards of $6.2 billion, $6.0 billion, and $178.0 million, respectively. Of the $6.2 billion U.S. federal net operating loss carryforwards, $6.1 billion may be carried forward indefinitely with utilization limited to 80% of taxable income, and the remaining $0.1 billion will begin to expire in 2032. The state net operating loss carryforwards begin to expire in 2026. Of the $178.0 million foreign net operating loss carryforwards, $165.2 million may be carried forward indefinitely, and the remaining $12.8 million will begin to expire in 2027. As of January 31, 2025, the Company also had federal and state tax credits of $482.9 million and $212.2 million, respectively. The federal tax credit carryforwards will expire beginning in 2032 if not utilized. The state tax credit carryforwards do not expire. Utilization of the Company’s net operating loss and tax credit carryforwards may be subject to annual limitation due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such an annual limitation could result in the expiration of the net operating loss and tax credit carryforwards before utilization. Foreign withholding taxes have not been provided for the cumulative undistributed earnings of the Company’s foreign subsidiaries as of January 31, 2025 due to the Company’s intention to permanently reinvest such earnings. Determination of the amount of unrecognized deferred tax liability related to these earnings is not practicable. The following table shows the changes in the gross amount of unrecognized tax benefits (in thousands):
| Fiscal Year Ended January 31,
| 2025 |  | 2024 |  | 2023
Beginning balance | $ | 115,253 |  |  | $ | 75,180 |  |  | $ | 57,715 |
Increases based on tax positions during the prior period | 655 |  |  | 12,708 |  |  | 1,816 |
Increases based on tax positions during the current period | 35,752 |  |  | 27,365 |  |  | 15,649 |
Ending balance | $ | 151,660 |  |  | $ | 115,253 |  |  | $ | 75,180 |
There were no interest and penalties associated with unrecognized income tax benefits for each of the fiscal years ended January 31, 2025, 2024, and 2023. Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next 12 months due to tax examination changes, settlement activities, or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, the Company does not anticipate any significant changes to unrecognized tax benefits over the next 12 months. The Company files income tax returns in the U.S. federal jurisdiction, various state jurisdictions, and in various international jurisdictions. Tax years 2012 and forward generally remain open for examination for federal and state tax purposes. Tax years 2020 and forward generally remain open for examination for foreign tax purposes. To the extent utilized in future years’ tax returns, net operating loss carryforwards at January 31, 2025 and 2024 will remain subject to examination until the respective tax year is closed. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (Inflation Act) into law. The Inflation Act contains certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations and an excise tax of 1% on stock repurchases. For the fiscal year ended January 31, 2025, the Inflation Act had no material impact to the Company, including its stock repurchase program.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration